Evidence map›Paper›PMID 18597688›Full record

ArticleBMC cancer2008

TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.

Michael D Oberst, Stacey J Beberman, Liu Zhao, Juan Juan Yin, Yvona Ward, Kathleen Kelly

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Michael D OberstCell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 1066, Bethesda, MD 20892, USA. michaeloberst@gmail.com
Stacey J Beberman
Liu Zhao
Juan Juan Yin
Yvona Ward
Kathleen Kelly
National Cancer Institute · USNational Institutes of Health · USCenter for Cancer Research · US

Funding

Laboratory of Genitourinary Cancer Pathogenesis Microscopy Core FacilityZICBC010947 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LAKE, ROSS · 2009 to 2025
$11.0M
Ras-mediated signals in human epithelial cell transformation and metastasisZIABC010607 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLY, KATHLEEN · 2009 to 2019
$3.9M
Cell and Cancer Biology Branch Confocal Microscopy CoreZ01BC010947 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WARD, YVONA · 2008 to 2008
$860k
Ras-mediated signals in human epithelial cell transformation and metastasisZ01BC010607 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLY, KATHLEEN · 2004 to 2008
$623k
Intramural NIH HHS
6 · The paper itself

Abstract

introductionSignaling downstream of Ras is mediated by three major pathways, Raf/ERK, phosphatidylinositol 3 kinase (PI3K), and Ral guanine nucleotide exchange factor (RalGEF). Ras signal transduction pathways play an important role in breast cancer progression, as evidenced by the frequent over-expression of the Ras-activating epidermal growth factor receptors EGFR and ErbB2. Here we investigated which signal transduction pathways downstream of Ras contribute to EGFR-dependent transformation of telomerase-immortalized mammary epithelial cells HME16C. Furthermore, we examined whether a highly transcriptionally regulated ERK pathway target, PHLDA1 (TDAG51), suggested to be a tumor suppressor in breast cancer and melanoma, might modulate the transformation process.

methodsCellular transformation of human mammary epithelial cells by downstream Ras signal transduction pathways was examined using anchorage-independent growth assays in the presence and absence of EGFR inhibition. TDAG51 protein expression was down-regulated by interfering small hairpin RNA (shRNA), and the effects on cell proliferation and death were examined in Ras pathway-transformed breast epithelial cells.

resultsActivation of both the ERK and PI3K signaling pathways was sufficient to induce cellular transformation, which was accompanied by up-regulation of EGFR ligands, suggesting autocrine EGFR stimulation during the transformation process. Only activation of the ERK pathway was sufficient to transform cells in the presence of EGFR inhibition and was sufficient for tumorigenesis in xenografts. Up-regulation of the PHLDA1 gene product, TDAG51, was found to correlate with persistent ERK activation and anchorage-independent growth in the absence or presence of EGFR inhibition. Knockdown of this putative breast cancer tumor-suppressor gene resulted in increased ERK pathway activation and enhanced matrix-detached cellular proliferation of Ras/Raf transformed cells.

conclusionOur results suggest that multiple Ras signal transduction pathways contribute to mammary epithelial cell transformation, but that the ERK signaling pathway may be a crucial component downstream of EGFR activation during tumorigenesis. Furthermore, persistent activation of ERK signaling up-regulates TDAG51. This event serves as a negative regulator of both Erk activation as well as matrix-detached cellular proliferation and suggests that TDAG51 opposes ERK-mediated transformation in breast epithelial cells.

Indexed as

Signal TransductionAnoikisCell Line, TransformedCell ProliferationCell Transformation, NeoplasticDoxycyclineExtracellular Signal-Regulated MAP KinasesFemaleHumansMammary Glands, HumanMicroarray AnalysisMutationOncogene Protein p21(ras)Recombinant ProteinsTranscription FactorsDoxycyclineExtracellular Signal-Regulated MAP KinasesOncogene Protein p21(ras)PHLDA1 protein, humanRecombinant ProteinsTranscription Factors

Identifiers

PMID18597688
PMCPMC2474852
OpenAlexW2035724274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.